Skip to main content

Advertisement

Log in

A comment from SIGIS, SIE and SIAMS: “Puberty blockers in transgender adolescents—a matter of growing evidence and not of ideology”

  • Comment
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. World Health Organization (2019) International statistical classification of diseases and related health problems, 11th edn. https://icd.who.int/. Accessed 10 June 2023

  2. American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders, 5th edn, text rev. American Psychiatric Association. https://doi.org/10.1176/appi.books.97808904257

  3. Austin A, Craig SL, D’Souza S, McInroy LB (2022) Among transgender youth: elucidating the role of interpersonal risk factors. J Interpers Violence 37(5–6):NP2696–NP2718. https://doi.org/10.1177/08862605209155542

    Article  PubMed  Google Scholar 

  4. Campbell T, Rodgers YVM (2023) Conversion therapy, suicidality, and running away: an analysis of transgender youth in the US. J Health Econ 89:102750. https://doi.org/10.1016/j.jhealeco.2023.102750

    Article  PubMed  Google Scholar 

  5. Coleman E, Radix AE, Bouman WP et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 23(Suppl 1):S1–S259. https://doi.org/10.1080/26895269.2022.2100644

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Hembree WC, Cohen-Kettenis PT, Gooren L et al (2017) Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 102(11):3869–3903. https://doi.org/10.1210/jc.2017-01658

    Article  PubMed  Google Scholar 

  7. Fisher AD, Ristori J, Bandini E et al (2014) Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIE-SIEDP-ONIG. J Endocrinol Invest 37(7):675–687. https://doi.org/10.1007/s40618-014-0077-6

    Article  PubMed  CAS  Google Scholar 

  8. Lee WG, Butler G, Carmichael P et al (2023) Urological and gynaecological considerations for the use of gonadotropin-releasing hormone analogues in transgender and nonbinary adolescents: a narrative review. Eur Urol Focus 9(1):35–41. https://doi.org/10.1016/j.euf.2022.11.002

    Article  PubMed  Google Scholar 

  9. Tordoff DM, Wanta JW, Collin A, Stepney C, Inwards-Breland DJ, Ahrens K (2022) Mental health outcomes in transgender and nonbinary youths receiving gender-affirming care. JAMA Netw Open 5(2):e220978. https://doi.org/10.1001/jamanetworkopen.2022.0978

    Article  PubMed  PubMed Central  Google Scholar 

  10. Carmichael P, Butler G, Masic U et al (2021) Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLoS ONE 16(2):e0243894. https://doi.org/10.1371/journal.pone.0243894

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Schagen SEE, Wouters FM, Cohen-Kettenis PT, Gooren LJ, Hannema SE (2020) Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones. J Clin Endocrinol Metab 105(12):e4252–e4263. https://doi.org/10.1210/clinem/dgaa604

    Article  PubMed  PubMed Central  Google Scholar 

  12. Vlot MC, Klink DT, den Heijer M, Blankenstein MA, Rotteveel J, Heijboer AC (2017) Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 95:11–19. https://doi.org/10.1016/j.bone.2016.11.008

    Article  PubMed  CAS  Google Scholar 

  13. Schagen SE, Cohen-Kettenis PT, Delemarre-van de Waal HA, Hannema SE (2016) Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med 13(7):1125–1132. https://doi.org/10.1016/j.jsxm.2016.05.004

    Article  PubMed  Google Scholar 

  14. Klaver M, de Mutsert R, Wiepjes CM et al (2018) Early hormonal treatment affects body composition and body shape in young transgender adolescents. J Sex Med 15(2):251–260. https://doi.org/10.1016/j.jsxm.2017.12.009

    Article  PubMed  Google Scholar 

  15. Klink D, Bokenkamp A, Dekker C, Rotteveel J (2015) Arterial hypertension as a complication of triptorelin treatment in adolescents with gender dysphoria. Endocrinol Metab Int J 2(1):36–38. https://doi.org/10.15406/emij.2015.02.00008

    Article  Google Scholar 

  16. Perl L, Segev-Becker A, Israeli G, Elkon-Tamir E, Oren A (2020) Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by testosterone treatment in transgender male adolescents: a pilot study. LGBT Health 7(6):340–344. https://doi.org/10.1089/lgbt.2020.0026

    Article  PubMed  Google Scholar 

  17. Moreira Allgayer RMC, Borba GDS, Moraes RS, Ramos RB, Spritzer PM (2023) The effect of gender-affirming hormone therapy on the risk of subclinical atherosclerosis in the transgender population: a systematic review. Endocr Pract 29(6):498–507. https://doi.org/10.1016/j.eprac.2022.12.017

    Article  PubMed  Google Scholar 

  18. Howerton I, Harris JK (2022) Transgender identity and cardiovascular disease. Transgend Health 7(5):407–415. https://doi.org/10.1089/trgh.2020.0188

    Article  PubMed  PubMed Central  Google Scholar 

  19. Valentine A, Davis S, Furniss A et al (2022) Multicenter analysis of cardiometabolic-related diagnoses in transgender and gender-diverse youth: a PEDSnet study. J Clin Endocrinol Metab 107(10):e4004–e4014. https://doi.org/10.1210/clinem/dgac469

    Article  PubMed  PubMed Central  Google Scholar 

  20. Levine SB, Brown GR, Coleman E et al (1998) The standards of care for gender identity disorders—Fifth edition. J Psychol Human Sex 11(2):1–34. https://doi.org/10.1300/J056v11n02_01

    Article  Google Scholar 

  21. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al (2009) Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94(9):3132–3154. https://doi.org/10.1210/jc.2009-0345

    Article  PubMed  CAS  Google Scholar 

  22. de Vries ALC, Hannema SE (2023) Growing Evidence and remaining questions in adolescent transgender care. N Engl J Med 388(3):275–277. https://doi.org/10.1056/NEJMe2216191

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. D. Fisher.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ristori, J., Motta, G., Meriggiola, M.C. et al. A comment from SIGIS, SIE and SIAMS: “Puberty blockers in transgender adolescents—a matter of growing evidence and not of ideology”. J Endocrinol Invest 47, 479–481 (2024). https://doi.org/10.1007/s40618-023-02173-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-023-02173-6

Navigation